10th Anniversary of Biomolecules—Recent Advances in Peptide and Protein Therapeutics

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Biological and Bio- Materials".

Deadline for manuscript submissions: closed (25 February 2022) | Viewed by 12243

Special Issue Editor


E-Mail Website
Guest Editor
Department of Molecular and Life Science, Hanyang University, Ansan 15588, Republic of Korea
Interests: microbiology and antimicrobial therapy

Special Issue Information

Dear Colleagues,

This year marks the 10th anniversary of the open access MDPI journal Biomolecules. To celebrate this important occasion, we are delighted and proud to celebrate with a series of Special Issues and events. To date, the journal has received more than 6000 contributions and published more than 2600 articles, and the journal website attracts more than 26,483 monthly page views. We would like to express our sincerest thanks to our readers, innumerable authors, anonymous peer reviewers, editors, and all the people working in some way for the journal who have made substantial contributions over the years. Without your support, we would never have made it this far.

To mark this important milestone, a Special Issue entitled “10th Anniversary of Biomolecules—Recent Advances in Peptide and Protein Therapeutics” is being launched. This Special Issue will collect research articles, and high-quality review papers in the research fields relating to peptide and protein therapeutics. We kindly encourage research groups working in various areas of Peptide and Protein Therapeutics to make contributions to this Special Issue.

Every scientific journal is a collaborative achievement among many scientists from all over the world, and we would like to thank all our authors and reviewers who have contributed to our journal for their support. In recognition of our authors’ continued support, Biomolecules is also pleased to announce that the “Biomolecules Best Paper Awards for Anniversary Special Issues” will be launched and granted to the best papers published in the Anniversary Special Issues. See details at:

https://www.mdpi.com/journal/biomolecules/awards

text

Prof. Chul-Su Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Drug delivery systems
  • Biologics
  • Nanotechnology
  • Infectious and inflammatory disease
  • Peptide
  • Protein–protein interaction
  • Therapeutic application
  • Diagnostic application

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 812 KiB  
Article
Effect of a Single Intrauterine Dose of Human Recombinant Galectin-1 Buffered on Pregnancy Rate in Inseminated Cows
by Erika da Silva Carvalho Morani, Helen Alves Penha, Fernando Sebastián Baldi Rey and Marcelo Roncoletta
Biomolecules 2022, 12(3), 419; https://doi.org/10.3390/biom12030419 - 9 Mar 2022
Cited by 1 | Viewed by 2167
Abstract
The objective was to evaluate the efficacy of a single dose of exogenous galectin-1 in improving the pregnancy rate in inseminated cows, comparing the pregnancy rate of the two groups (treatment and control Groups) into 107 contemporary groups (YG) established. An ultrasound exam [...] Read more.
The objective was to evaluate the efficacy of a single dose of exogenous galectin-1 in improving the pregnancy rate in inseminated cows, comparing the pregnancy rate of the two groups (treatment and control Groups) into 107 contemporary groups (YG) established. An ultrasound exam determined the pregnancy rate performed 25 to 35 days after the fixed-time artificial insemination (FTAI) of breeding beef cows (n = 3469). The pregnancy rate of cows that received a single dose of eGAL-1 (200 ± 10 µg), with an intrauterine administration (n = 1901), was compared with the pregnancy rate of cows inseminated using a conventional AI protocol (n = 1568), both comparing into the same YG. YGs were created considering the grouping of cows belonging to the same farm, with the same nutritional score and management, inseminated by the same inseminator and semen batch, and using the same estrus synchronization protocol). The statistical method used calculated the probability of obtaining pregnancy within each group. The administration of a single dose of eGAL-1 can increase the probability of obtaining pregnancy in beef cows by up to 8.68% (p < 0.0001), suggesting that a single dose of eGAL-1 during the FTAI procedure was reasonable in the beef cattle AI routine and can improve the pregnancy rate considerably. Full article
Show Figures

Figure 1

18 pages, 6653 KiB  
Article
HSP70 Ameliorates Septic Lung Injury via Inhibition of Apoptosis by Interacting with KANK2
by Qing Pei, Wei Ni, Yihang Yuan, Jing Yuan, Xiong Zhang and Min Yao
Biomolecules 2022, 12(3), 410; https://doi.org/10.3390/biom12030410 - 7 Mar 2022
Cited by 10 | Viewed by 2667
Abstract
Acute lung injury is the most common type of organ damage with high incidence and mortality in sepsis, which is a poorly understood syndrome of disordered inflammation. The aims of this study are to explore whether heat shock protein 70 (HSP70), as a [...] Read more.
Acute lung injury is the most common type of organ damage with high incidence and mortality in sepsis, which is a poorly understood syndrome of disordered inflammation. The aims of this study are to explore whether heat shock protein 70 (HSP70), as a molecular chaperone, attenuates the septic lung injury, and to understand the underlying mechanisms. In our study, treatment with HSP70 ameliorated the survival rate, dysfunction of lung, inflammation, and apoptosis in cecal ligation and puncture (CLP)-treated mice as well as in LPS-treated human alveolar epithelial cells. Furthermore, HSP70 interacted with KANK2, leading to reversed cell viability and reduced apoptosis-inducing factor (AIF) and apoptosis. Additionally, knockdown of KANK2 in epithelial cells and deletion of hsp70.1 gene in CLP mice aggravated apoptosis and tissue damage, suggesting that interaction of KANK2 and HSP70 is critical for protecting lung injury induced by sepsis. HSP70 plays an important role in protection of acute lung injury caused by sepsis through interaction with KANK2 to reduce AIF release and apoptotic cell. HSP70 is a novel potential therapeutic approach for attenuation of septic lung injury. Full article
Show Figures

Figure 1

Review

Jump to: Research

21 pages, 2234 KiB  
Review
A Review on Health-Promoting, Biological, and Functional Aspects of Bioactive Peptides in Food Applications
by Seyed Hadi Peighambardoust, Zohreh Karami, Mirian Pateiro and José M. Lorenzo
Biomolecules 2021, 11(5), 631; https://doi.org/10.3390/biom11050631 - 23 Apr 2021
Cited by 94 | Viewed by 6574
Abstract
Food-derived bioactive peptides are being used as important functional ingredients for health-promoting foods and nutraceuticals in recent times in order to prevent and manage several diseases thanks to their biological activities. Bioactive peptides are specific protein fractions, which show broad applications in cosmetics, [...] Read more.
Food-derived bioactive peptides are being used as important functional ingredients for health-promoting foods and nutraceuticals in recent times in order to prevent and manage several diseases thanks to their biological activities. Bioactive peptides are specific protein fractions, which show broad applications in cosmetics, food additives, nutraceuticals, and pharmaceuticals as antimicrobial, antioxidant, antithrombotic, and angiotensin-I-converting enzyme (ACE)-inhibitory ingredients. These peptides can preserve consumer health by retarding chronic diseases owing to modulation or improvement of the physiological functions of human body. They can also affect functional characteristics of different foods such as dairy products, fermented beverages, and plant and marine proteins. This manuscript reviews different aspects of bioactive peptides concerning their biological (antihypertensive, antioxidative, antiobesity, and hypocholesterolemic) and functional (water holding capacity, solubility, emulsifying, and foaming) properties. Moreover, the properties of several bioactive peptides extracted from different foods as potential ingredients to formulate health promoting foods are described. Thus, multifunctional properties of bioactive peptides provide the possibility to formulate or develop novel healthy food products. Full article
Show Figures

Figure 1

Back to TopTop